Clinical Trials Browser

Phase 1/2 × Hematologic Neoplasms × Leflunomide × Clear all

NCT04532372 2024-07-03

Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy

Phase 1/2 Completed

2 enrolled 7 charts

Other hematologic neoplasm

Hematologic Neoplasms